For IPO Boutique's "scale of 1 to 5" BUY rating on Celsus Therapeutics, and our comprehensive analysis, click "Buy Market Research".
About Celsus Therapeutics (adapted from Celsus Therapeutics prospectus): They are a clinical-stage biotech developing novel anti-inflammatory synthetic drugs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CLTX (trades on OTCBB "CLSXD")" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
Used our Comprehensive Single Promo Advisory and want more?